Hyperbaric Oxygen Clinics

Hyperbaric oxygen therapy (HBOT) — breathing 100% oxygen at 2-3 atmospheres in a pressurised chamber — is established medicine with a bounded formulary: the recognised indication list (curated by the Undersea and Hyperbaric Medical Society and reflected in FDA and payer frameworks) runs to roughly fourteen conditions, including decompression sickness (the founding use), carbon monoxide poisoning, arterial gas embolism, gas gangrene and necrotising infections, crush injuries, delayed radiation tissue injury (one of the workhorse modern uses), compromised grafts and flaps, selected refractory diabetic foot ulcers and refractory osteomyelitis, and sudden sensorineural hearing loss and central retinal artery occlusion in defined windows. The physiological logic is straightforward — dissolving enough oxygen in plasma to oxygenate tissue independently of haemoglobin, shrinking gas bubbles, and stimulating vascularisation in radiation-damaged tissue — and the treatment is delivered in accredited facilities, at real pressures, with physician oversight, because oxygen at pressure is a drug with a dose. Everything in this hub's controversy begins where that list ends.

The off-label economy sells HBOT for autism, cerebral palsy, stroke recovery, traumatic brain injury and concussion, multiple sclerosis, Lyme, fibromyalgia, cancer (adjunct claims), anti-ageing and general “cellular optimisation” — a catalogue mapping precisely onto this collection's desperate-buyer registry, at $150-500 per session in courses of 40-plus. The evidence, scored: autism — the flagship cautionary tale: after small positive pilots drove a parental market, the rigorous randomised trial found no benefit over sham pressure, and no responsible body recommends it (sessions continue being sold regardless); stroke and TBI/post-concussion — decades of trials with a persistent problem: sham-controlled studies keep showing both arms improving (pressurised air behaving like pressurised oxygen), leaving a literature proponents read as “even sham works” and methodologists read as placebo-plus-ritual; MS — trialled extensively in the 1980s-90s, abandoned as null; cancer — no adjunct benefit established, with legitimate narrow uses only in radiation injury; “anti-ageing” — one small Israeli telomere study launched a thousand longevity-clinic menus, unreplicated at outcome level. The one honest frontier: long COVID — small randomised trials (notably Israeli) reporting cognitive and fatigue improvements, genuinely promising, genuinely preliminary, and already being sold as settled.

The market's structural trick is pressure itself. Medical HBOT operates at 2.0-3.0 atmospheres absolute with 100% oxygen; the consumer boom runs substantially on “mild HBOT” — soft inflatable chambers at ~1.3 ATA, often on air or concentrator oxygen — which cannot deliver the doses behind any indication on the established list: the physics gap between 1.3 ATA air and 2.4 ATA oxygen is roughly the gap between a hill walk and the drug. These portable chambers (FDA-cleared only for acute mountain sickness) anchor home-rental and wellness-studio economics, borrow the entire HBOT literature in their marketing, and add their own safety file — untrained operation, ignition risks, and zero physician screening. The honest translation for consumers: “hyperbaric” on a wellness menu usually names the chamber shape, not the therapy; asking “what pressure, what oxygen source, what protocol” sorts the market in three questions — and the answers at most wellness studios disqualify the session from the evidence being quoted.

HBOT's risks are physics, and physics attends every session including the useless ones. Fire is the catastrophic one: oxygen-enriched pressurised environments turn minor ignition sources into instant infernos — chamber fires have killed patients repeatedly worldwide, and the 2025 death of a five-year-old boy in a chamber fire at a Michigan clinic (with criminal charges following, and further US incidents the same period) put the unaccredited-facility problem on front pages: accreditation regimes exist precisely because grounding, materials control and no-ignition protocols are life-critical, and the wellness tier is where they thin out. The routine risks: middle-ear and sinus barotrauma (the common one), transient myopia, confinement anxiety, and central nervous system oxygen toxicity — seizures at higher pressures, the reason protocols cap dose and staff watch. Contraindications (untreated pneumothorax absolutely; certain drugs and lung disease relatively) are why physician screening is part of the therapy. None of these risks is large in accredited practice — that is the point: the safety architecture is the medicine's half, and buying the chamber without the architecture buys the physics without the protection.

HBOT is a masterclass in why plausible-mechanism therapies resist honest evaluation. The mechanism is too good: oxygen matters to everything, so every condition can borrow the story — the universal-mechanism problem this collection meets from stem cells to NAD. The ritual is maximal: an hour inside a pressurised vessel, technology humming, staff attending — sham-controlled trials keep measuring exactly how therapeutic that feels, and the stroke/TBI literature is the residue. The desperation gradient is steep: parents of autistic children and brain-injury families are the market's core, making null results commercially irrelevant. The frontier is real enough to launder the rest: radiation injury yesterday, long COVID possibly tomorrow — genuine additions to the list happen, and each one recharges the halo over the whole menu. The reader's toolkit follows: distinguish the list (established, accredited, insured), the frontier (registered trials — join them rather than buying the answer early), and the menu (everything else); demand sham-controlled evidence for any brain claim; and price the course honestly — 40 sessions at $250 is $10,000 of hope the null trials already spent.

If you have a listed indication — radiation tissue injury, a qualifying diabetic foot ulcer, CO poisoning, sudden hearing loss in the window: HBOT is real medicine; insist on an accredited facility (UHMS accreditation or national equivalent), hard chambers at therapeutic pressures, and physician oversight — and expect insurance to participate, because the list is the list. If you are being sold HBOT for autism, stroke, TBI, MS, Lyme, cancer or ageing: the trials came back null or sham-equivalent where they exist at all; keep the $10,000 and fund the interventions with evidence. If long COVID brought you here: the small trials are genuinely encouraging — the right move is a registered trial or a specialist conversation, not a wellness-studio package sold on preprints. Never enter unaccredited or soft chambers casually: pressure and oxygen are the same physics at every price point, chamber fires kill, and 1.3 ATA “mild HBOT” delivers neither the studied doses nor the safety architecture. And the sorting questions that cost nothing: what pressure, what oxygen source, whose accreditation, which trial — four answers separate the medicine from the menu.